Zecotek Initiating Commercialization - Grants Manufacturing Contract for New-Generation Solid-State Photo Detectors.
Vancouver, July 3, 2007 - Zecotek Medical Systems Inc. (TSX-V: ZMS; Frankfurt: W1I.F) today announced that it has granted the Malaysian Institute for Micro-electronics Systems (MIMOS) based in Kuala Lumpur a contract to manufacture the company’s new-generation solid-state photo detectors (MAPD). MIMOS is Malaysia’s premier center for advanced micro-electronics technology and manufacturing.
“We are extremely impressed by the technical skills and professional integrity of the engineering and management team at MIMOS,” said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Medical Systems. “We are confident that the MAPD will be produced with the highest quality and at a cost that gives Zecotek a significant advantage over competing products. We have been approached by a number of potential customers from both medical and non-medical industries who will receive first-run production samples for further testing.”
MIMOS has committed to deliver first-run production samples to a variety of end-users by mid-July for additional assessment. Upon successful results, full production is expected in September (Zecotek’s Q1 fiscal 2008) with first shipments planned for the medical imaging, high-energy physics, and radio telescope industries.
Zecotek’s proprietary solid-state photon counters, MAPD, have been designed to offer significant cost and performance advantages over the current vacuum tube based photo multiplier tubes (PMT). Recent testing completed by the University of Washington demonstrated that Zecotek’s MAPD, in combination with its patented LFS scintillation crystal, outperform current PMT’s in critical imaging parameters. The pre-production MAPDs developed in Zecotek labs have also been successfully tested by third-party entities including major medical imaging equipment manufactures, government and international research centers and laboratories.
PMT based photo-detection devices form a major cost component in the US$1 billion market for PET and PET-CT scanners, representing approximately one-third of the cost of each unit.
Existing PMT’s are also key components of medical inspection devices used in blood analysis and DNA sequencing.
Additional non-medical applications include: gamma ray detectors for homeland security, environmental monitoring, industrial control systems, robotics, biomedical testing, navigation and guidance systems, laser radars and high-energy physics.
– 30 –
Zecotek Medical Systems (TSX-V: ZMS; Frankfurt: W1I.F) is a bio-photonics technology company developing high-performance crystals, photo detectors, medical lasers, optical imaging and 3D display technologies for commercial applications in the medical diagnostics and high-tech industry. Founded in 2003, the company has three distinct operating divisions: medical imaging, medical lasers and 3D display and labs located in Canada, Singapore and Russia. Zecotek commercializes its novel, patented and patent-pending bio-photonic technologies directly and through strategic alliances and joint ventures with multinational OEMs, distributors and other industry leaders.
This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.
For additional information on Zecotek Medical Systems and our technologies please see our website at Zecotek Photonics.
For additional information please contact:
CFO; VP Corporate Development
T: (604) 827-5203
Caliber Capital Partners
T: (778) 327-6678
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at Zecotek Photonics.